Jump to content

Barton Haynes

Add links
From Wikipedia, the free encyclopedia

Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) in 2012.[1] In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery (CAVD), which was funded by the Bill and Melinda Gates Foundation in 2006.[2][3]

Haynes was the director of the Center for HIV/AIDS Vaccine Immunology (CHAVI), which was funded by the NIAID from 2005 to 2011 to overcome obstacles to HIV vaccine development.[4][5] The "big science" approach of the CHAVI grant enabled the following scientific discoveries by the CHAVI team: 1) the delineation of HIV-1 transmitted/founder viruses that are responsible for the transmission of HIV/AIDS; 2) the discovery of host tolerance mechanisms that limit the induction of broad neutralizing antibodies in HIV-1 infection; 3) the fine mapping and delineation of the immunological events that transpire during the earliest days of HIV-1 infection; 4) the discovery of new genes and gene mutations/duplications that contribute to HIV-1 control and progression; 5) the design of mosaic T cell and B cell Env vaccine candidates to overcome HIV diversity; 6) the discovery of the immune correlates of risk of infection in the RV144 trial;[6] 7) the isolation of rare broad neutralizing HIV antibodies and their ancestor antibodies; and 8) the development of a new strategy for vaccine development called B Cell Lineage Immunogen Design.[7][8] He led the group that deciphered the maturation pathways of several types of broadly neutralizing antibodies that point the way to vaccine designs, and has worked out the immunobiology of HIV-host interactions that control broad neutralizing antibody development.[9][10][11]

Haynes received his bachelor's degree from the University of Tennessee in 1969 and his M.D. from Baylor College of Medicine in 1973. He completed his internship and residency at Duke University Medical Center in 1975. After conducting research for five years at the National Institute of Allergy and Infectious Diseases from 1975 to 1980, Haynes returned to Duke as a member of the faculty in the department of medicine in 1980.[12] He served as Chief of the Division of Rheumatology, Allergy and Clinical Immunology from 1987 to 1995, and as chair of the department of medicine from 1995 to 2002 at Duke University Medical Center. Haynes established the Duke Human Vaccine Institute in 1990 to support interdisciplinary efforts across Duke to develop vaccines and therapeutics for HIV and other emerging infections.[13][14]

Haynes served as a member of the NIAID Advisory Council,[15] Chairman of the National Academy of Sciences Institute of Medicine Roundtable for Development for Drugs and Vaccines against AIDS, and currently is chair of the NIAID AIDS Vaccine Research Working Group that advises the National Institutes of Health (NIH) regarding the national HIV vaccine effort. Haynes served on the NIAID Blue Ribbon Committees on Bioterrorism and Emerging Infections held in February and October 2002. He received the Alexander Fleming Award for Lifetime Achievement from the Infectious Diseases Society of America in 2011 and the Ralph Steinman Award for Human Immunology Research from the American Association of Immunologists in 2013.[16][17] He was the recipient of the Duke Award for Basic Science Mentoring in 2011. Haynes is a Fellow of the Infectious Diseases Society of America and is a member of the Association of American Physicians, the National Academy of Sciences Institute of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences.[18]

References

[edit]
Scholia has a profile for Barton Haynes (Q4865631).
  1. ^ National Institutes of Health." NIH Awards $31 Million for HIV/AIDS Vaccine Immunology and Immunogen Discovery." Press Release. July 11, 2012.
  2. ^ Cohen, Jon (2006). "Gates Foundation Doubles Support for AIDS Vaccine Research". Science. 313 (5785): 283. doi:10.1126/science.313.5785.283a. PMID 16857908. S2CID 6506698.
  3. ^ Collaboration for AIDS Vaccine Discovery. About the Grantees.
  4. ^ National Institutes of Health. "NIAID Funds Center for HIV/AIDS Vaccine Immunology (CHAVI) Archived August 2, 2009, at the Wayback Machine." Press Release. July 14, 2005.
  5. ^ National Institute of Allergy and Infectious Diseases. Center for HIV/AIDS Vaccine Immunology. Questions and Answers Archived August 30, 2009, at the Wayback Machine.
  6. ^ Haynes, BF; Gilbert, PB; McElrath, MJ; Zolla-Pazner, S; Tomaras, GD; Alam, SM; Evans, DT; Montefiori, DC; Karnasuta, C; Sutthent, R; et al. (2012). "Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial". N. Engl. J. Med. 366 (14): 1275–86. doi:10.1056/NEJMoa1113425. PMC 3371689. PMID 22475592.
  7. ^ Haynes, BF; Kelsoe, G; Harrison, SC; Kepler, TB (2012). "B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study". Nat. Biotechnol. 30 (5): 423–33. doi:10.1038/nbt.2197. PMC 3512202. PMID 22565972.
  8. ^ Center for HIV/AIDS Vaccine Immunology. Progress Reports Archived August 25, 2013, at the Wayback Machine.
  9. ^ Bonsignori, Mattia (March 2, 2016). "Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody". Cell. 165 (2): 449–63. doi:10.1016/j.cell.2016.02.022. PMC 4826291. PMID 26949186.
  10. ^ Haynes, Barton (March 9, 2016). "HIV-Host Interactions: Implications for Vaccine Design". Cell Host Microbe. 19 (3): 292–303. doi:10.1016/j.chom.2016.02.002. PMC 4823811. PMID 26922989.
  11. ^ Verkoczy, Laurent (May 9, 2014). "AIDS/HIV. Host controls of HIV neutralizing antibodies". Science. 344 (6184): 588–589. doi:10.1126/science.1254990. PMC 4162091. PMID 24812389.
  12. ^ Simon Noble. "An Interview with Barton Haynes: A new virtual Center Archived June 4, 2011, at the Wayback Machine." IAVI Report. 2005 Sep/Oct 9(4);4
  13. ^ Duke Human Vaccine Institute. About the Institute Archived March 4, 2011, at Archive-It.
  14. ^ UNC-TV. The New Age of HIV/AIDS. Interview: Bart Haynes, M.D. Archived April 6, 2009, at the Wayback Machine
  15. ^ James Hadley. "HHS Secretary Names Five to NIAID Advisory Council Archived August 30, 2009, at the Wayback Machine." National Institute of Allergy and Infectious Diseases. Feb. 26, 1999
  16. ^ Infectious Diseases Society of America. Alexander Fleming Award Winners Archived 2012-07-23 at the Wayback Machine.
  17. ^ American Association of Immunologists. 2013 AAI Award Recipients Archived 2013-03-20 at the Wayback Machine.
  18. ^ Duke University Medical Center Office of Publications. "Haynes Elected to Academy." Inside DUMC 2002-09: May 07, 2007 Volume 16 No. 9
Retrieved from "https://en.wikipedia.org/w/index.php?title=Barton_Haynes&oldid=1131404971"